bioAffinity Technologies, Inc. (BIAFW)
- Previous Close
0.1700 - Open
0.1500 - Bid --
- Ask --
- Day's Range
0.1711 - 0.1711 - 52 Week Range
0.1711 - 0.1711 - Volume
30 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) 3.03
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
www.bioaffinitytech.comRecent News: BIAFW
View More
Compare To: BIAFW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIAFW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-96.56%
Return on Assets (ttm)
-75.95%
Return on Equity (ttm)
-242.44%
Revenue (ttm)
9.36M
Net Income Avi to Common (ttm)
-9.04M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
1.11M
Total Debt/Equity (mrq)
57.69%
Levered Free Cash Flow (ttm)
-3.95M